English | 繁體

Search in the results

UM

Browse/Search Results:  1-4 of 4 Help

Selected(0)Clear Items/Page:    Sort:
Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin Journal article
Xu, Hongling, Yuan, Mingming, Niu, Kailin, Yang, Wei, Jiang, Maoyuan, Zhang, Lei, Zhou, Jing. Involvement of Bile Acid Metabolism and Gut Microbiota in the Amelioration of Experimental Metabolism-Associated Fatty Liver Disease by Nobiletin[J]. Molecules, 2024, 29(5), 976.
Authors:  Xu, Hongling;  Yuan, Mingming;  Niu, Kailin;  Yang, Wei;  Jiang, Maoyuan; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.2/4.6 | Submit date：2024/04/02
Bile Acid  Farnesoid x Receptor  Gut Microbiota  Metabolism-associated Fatty Liver Disease  Nobiletin  
Anti-inflammatory effect of Rhein on ulcerative colitis via inhibiting PI3K/Akt/mTOR signaling pathway and regulating gut microbiota Journal article
Dong, Lingling, Du, Hongling, Zhang, Minyue, Xu, Haiting, Pu, Xiulan, Chen, Qiyan, Luo, Ruifeng, Hu, Yichen, Wang, Yitao, Tu, He, Zhang, Jinming, Gao, Fei. Anti-inflammatory effect of Rhein on ulcerative colitis via inhibiting PI3K/Akt/mTOR signaling pathway and regulating gut microbiota[J]. Phytotherapy Research, 2022, 36(5), 2081 - 2094.
Authors:  Dong, Lingling;  Du, Hongling;  Zhang, Minyue;  Xu, Haiting;  Pu, Xiulan; et al.
Favorite | TC[WOS]:101 TC[Scopus]:110  IF:6.1/7.0 | Submit date：2022/05/17
Antiinflammation  Gut Microbiota  Network Pharmacology  Pi3k/akt/mtor Signaling Pathway  Rhein  Ulcerative Colitis  
Methylaervine as Potential Lead Compound Against Cervical Carcinoma: Pharmacologic Mechanism Prediction based on Network Pharmacology Journal article
Dan, Wenjia, Xu, Yujie, Gu, Hongling, Gao, Jixiang, Dai, Jiangkun. Methylaervine as Potential Lead Compound Against Cervical Carcinoma: Pharmacologic Mechanism Prediction based on Network Pharmacology[J]. Current Computer-Aided Drug Design, 2022, 18(1), 73-80.
Authors:  Dan, Wenjia;  Xu, Yujie;  Gu, Hongling;  Gao, Jixiang;  Dai, Jiangkun
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:1.5/1.5 | Submit date：2022/03/28
Methylaervine  Synthesis  Antitumor Activity  Adme Study  Network Pharmacology  Docking  
Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms Journal article
Rongjia Zhu, Tingdong Yan, Yingmei Feng, Yan Liu, Hongcui Cao, Gongxin Peng, Yanlei Yang, Zhen Xu, Jingqi Liu, Wei Hou, Xiaoyue Wang, Zhe Li, Luchan Deng, Shihua Wang, Jing Li, Qin Han, Hongling Li, Guangliang Shan, Yinghao Cao, Xingyan An, Jianshe Yan, Zhonghui Zhang, Huafei Li, Xuebin Qu, Jiaqi Zhu, Shumin Zhou, Jiao Wang, Fengchun Zhang, Jinming Gao, Ronghua Jin, Dayong Xu, Yan Qing Ma, Tao Huang, Shuang Peng, Zhi Zheng, Ilia Stambler, Eric Gilson, Lee Wei Lim, Alexey Moskalev, Antonio Cano, Sasanka Chakrabarti, Brun Ulfhake, Huanxing Su, Haoying Xu, Sihuan Xu, Feng Wei, Holly M. Brown-Borg, Kyung Jin Min, Georgina Ellison-Hughes, Calogero Caruso, Kunlin Jin, Robert Chunhua Zhao. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms[J]. Cell Research, 2021, 31(12), 1244-1262.
Authors:  Rongjia Zhu;  Tingdong Yan;  Yingmei Feng;  Yan Liu;  Hongcui Cao; et al.
Favorite | TC[WOS]:84 TC[Scopus]:87  IF:28.1/36.4 | Submit date：2022/01/14